ADC Engineering Optimization

ADC engineering optimization is the episode’s frame for antibody-drug conjugates as a combinatorial engineering field. In vol.117.生物医药的2025：抄底中国、研发焦虑和新王继位, [[XiaoPTeacher|小P老师]] breaks ADCs into antibody, payload, and linker, then argues that many combinations can change pharmacology, efficacy, safety, manufacturability, and deal value.

The source says this kind of iterative optimization may fit Chinese biotech strengths in engineering and execution. It does not treat ADCs as a guaranteed revolution: assets can be licensed for large sums and still be stopped later if data, safety, or strategic fit disappoint.

Key Claims

• ADC value depends on the interaction among antibody targeting, linker behavior, and payload effect.
• China’s strength in engineering optimization may help it produce second-wave ADC assets.
• Large licensing deals do not guarantee later success or approval.
• Dual-Payload ADC is a more complex extension of the same optimization logic.

Connections

• Kelun-Biotech / 科伦博泰 and Innovent Biologics / 信达生物 - Chinese company examples named in the source.
• Biotech License-Out Arbitrage and China Biotech Asset Repricing - transaction context for ADC assets.
• Domain Know-How Moat - broader wiki frame for complex execution knowledge.
• Finite-Game Biotech Competition - mature-platform competition context.